<DOC>
	<DOC>NCT01065766</DOC>
	<brief_summary>This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of sitagliptin/metformin (JANUMET) through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs.</brief_summary>
	<brief_title>Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Has type 2 diabetes mellitus Is treated with sitagliptin/metformin within local label for the first time Has a contraindication to sitagliptin/metformin according to the local label Is treated with sitagliptin/metformin before contract and out of enrollment period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Non-Insulin-Dependent</keyword>
</DOC>